Plus Therapeutics (PSTV) Expected to Announce Quarterly Earnings on Wednesday

Plus Therapeutics (NASDAQ:PSTV) is expected to be announcing its Q1 2025 earnings results before the market opens on Wednesday, May 21st. Analysts expect the company to announce earnings of ($0.24) per share and revenue of $1.11 million for the quarter.

Plus Therapeutics (NASDAQ:PSTV) last issued its quarterly earnings data on Thursday, March 27th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.51) by ($0.16). The firm had revenue of $1.80 million during the quarter, compared to analyst estimates of $1.19 million. On average, analysts expect Plus Therapeutics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Plus Therapeutics Trading Down 17.1%

Plus Therapeutics stock opened at $0.42 on Monday. The firm has a market capitalization of $7.14 million, a P/E ratio of -0.17 and a beta of 0.88. The stock has a fifty day moving average price of $0.81 and a 200 day moving average price of $1.05. Plus Therapeutics has a 52 week low of $0.24 and a 52 week high of $2.67.

Analyst Ratings Changes

Several research firms recently commented on PSTV. D. Boral Capital reiterated a “hold” rating on shares of Plus Therapeutics in a research note on Monday, May 5th. Ascendiant Capital Markets upped their target price on Plus Therapeutics from $19.00 to $20.00 and gave the company a “buy” rating in a research note on Monday, April 21st. D Boral Capital lowered Plus Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Monday, May 5th. Finally, HC Wainwright dropped their target price on Plus Therapeutics from $8.00 to $5.50 and set a “buy” rating for the company in a research note on Friday, March 28th.

Plus Therapeutics Company Profile

Plus Therapeutics, Inc, a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead radiotherapeutic drug candidate is rhenium (186Re) obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers.